Catabasis To Present The MoveDMD Trial Of Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy For DMD, At The American Neurological Association’s 2016 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Catabasis will present the MoveDMD trial of edasalonexent for the treatment of Duchenne muscular dystrophy (DMD) at the American Neurological Association’s (ANA) 2016 Annual Meeting. The ANA 2016 Annual Meeting is being held October 16 – October 18, 2016, in Baltimore, MD, at the Baltimore Marriott Waterfront Hotel.